Niclosamide in Leukemia

Drug repurposing · Preclinical evidence

Niclosamide in Leukemia: What the Preclinical Studies Show

Tumour growth, survival and leukemia stem cells—read alongside the dose, route and experimental model.

Evidence review · 19 October 2026

Niclosamide has produced measurable antileukemic effects in animals, including smaller tumours, lower leukemia burden and longer survival. These findings go beyond changes in signalling proteins in a culture dish. Their relevance, however, depends on which compound was administered, how it reached the animals, and whether treatment began before or after substantial disease developed.

The most informative reading brings together two kinds of evidence: subcutaneous tumour experiments that quantify growth inhibition, and disseminated leukemia models that test disease burden, survival or the ability to initiate leukemia again. Neither alone establishes efficacy in patients.

First, identify the compound

The literature often uses “niclosamide” as shorthand even when the animal experiment uses a modified molecule. Keeping those distinctions visible prevents an injected derivative’s results from being attributed to a conventional oral tablet.

Parent niclosamide

The original anthelmintic. Leukemia studies include both oral administration and intraperitoneal injection. Route matters even when the molecule is the same. [1] [5]

p-Niclosamide

A water-soluble phosphate derivative used in several AML, CML and B-ALL mouse experiments. Its injected regimens are separate evidence from oral parent-drug treatment. [2] [6]

MB1-47

A niclosamide-related mitochondrial uncoupler developed to improve drug exposure. It provides evidence for a related therapeutic strategy, not for the efficacy of ordinary niclosamide tablets. [9]

Reading the doses: mg/kg below denotes the dose administered to mice. IP means intraperitoneal injection; oral gavage delivers a measured dose into the stomach. These are experimental regimens, not human dose recommendations.

How much smaller were the tumours?

A 2022 T-ALL study implanted CCRF-CEM cells subcutaneously in NOD/SCID mice (five/group). Niclosamide was injected IP three times weekly from day 7; endpoint: day 26. [1]

Swipe or drag to explore the table
Day-26 tumour volume: reported means ± SEM; reductions calculated against control
TreatmentMouse dose per injectionVolume (mm³)Lower than control
ControlVehicle1,206 ± 257.0Reference
Niclosamide5 mg/kg458.4 ± 106.262.0%
Niclosamide20 mg/kg392.8 ± 92.4967.4%
Dexamethasone1 mg/kg202.9 ± 29.0883.2%

Calculation: 100 × (1 − treated mean ÷ control mean). SEM: standard error of the mean. Dexamethasone was a separate comparator. All treatment volumes were lower than control (P < 0.05). [1, Figure 5]

Growth inhibition is the supported claim

These differences do not establish regression from pretreatment size. All groups survived to the endpoint; a survival advantage was not demonstrated. [1]

Other studies also measured tumour growth

Study stays visible while scrolling
Additional leukemia-derived subcutaneous tumours
Study / modelCompound & mouse regimenMeasured finding
AML · 2010
HL-60
p-Niclosamide, 40 mg/kg/day IP for 15 days; seven mice/group.Suppressed tumour-volume growth; lower excised tumour weight at day 19. [2, Figure 5]
CML · 2018
KBM5-T315I
p-Niclosamide, 40 mg/kg IP twice daily for approximately two weeks, beginning after tumours became palpable.Lower tumour volumes than vehicle and imatinib; the mutation confers imatinib resistance. [3, Figure 6]
T-ALL · 2024
CCRF-CEM
Parent niclosamide, 20 mg/kg IP three times weekly, day 7 to day 28; six mice/group.Reduced tumour volume. Adding α-ketoglutarate did not improve the in vivo effect. [4, Figure 8]

Exact endpoint means were not verified for these three datasets, so no percentage reduction is assigned here. A graph showing growth inhibition supports the direction of effect; it does not justify an apparently precise percentage extracted by eye.

Subcutaneous models make tumours easy to measure, but they place leukemia cells in an artificial solid mass. They do not reproduce the full biology of leukemia circulating through blood, occupying marrow and infiltrating organs. Consequently, the following systemic models deserve greater weight when assessing relevance to leukemia.

Systemic disease and survival: the more relevant tests

Swipe, drag or use the arrows
Survival values are medians: control → treated
ModelCompound, dose & timingAnimal outcomeInterpretation
AML PDX 186
2018
Parent niclosamide, 200 mg/kg orally daily, starting one day after transplantation.41 → 51.5 days; P = 0.0015; eight mice/group.Positive survival result, but treatment began very early. [5]
AML PDX 3123
2018
Same oral dose; treatment began four weeks after transplantation, with substantial leukemia burden.67 → 72 days; not statistically significant. Burden reduction was temporary.More demanding established-disease experiment; weaker efficacy. [5]
T315I BCR-ABL model
2018
Disseminated BaF3-T315I cells; p-niclosamide 40 mg/kg IP twice daily for two weeks.18 → 24 days; P = 0.0346; lower bioluminescent burden.An engineered resistant-leukemia model, separate from the subcutaneous CML experiment. [3]
B-ALL NALM-6-Luc
2024
p-Niclosamide, 25 mg/kg IP twice daily for three weeks.26.5 → 32.5 days; six mice/group; lower imaging signal and marrow/spleen leukemia-cell fractions.Evidence of systemic activity with an injected derivative. [6]

PDX means patient-derived xenograft: human leukemia cells transplanted into mice. Bioluminescence and leukemia-cell fractions measure burden; neither is a tumour-volume measurement.

Preventing expansion immediately after transplantation is a different challenge from controlling established leukemia. Both designs are informative, but established-disease experiments more closely address the therapeutic question.

How strong is the leukemia stem-cell evidence?

Reducing cells with a “stem-like” surface-marker profile is suggestive. A more demanding test asks whether remaining cells can regenerate leukemia after transplantation into another animal.

A 2017 CML study addressed that functional question. In a BCR-ABL-driven mouse model, researchers used p-niclosamide 30 mg/kg/day IP, with or without imatinib 100 mg/kg/day orally, for two weeks. Treatment disrupted the p65–FOXM1–β-catenin regulatory network and impaired leukemia-initiating activity. The combination yielded no detected engraftment in secondary recipients across the three tested cell doses at 16 weeks. [7]

This is stronger evidence of impaired self-renewal than a marker change alone. It remains an assay-bounded mouse result: “no detected engraftment” is not equivalent to proving every malignant stem cell was eliminated in a patient.

The same paper’s human-cell transplantation experiment needs a separate label: CML CD34-positive cells were exposed to 2.5 µM niclosamide for 48 hours outside the animal before transplantation. That tests the consequences of ex vivo exposure; it does not show that dosing a mouse achieved the same exposure in human leukemia cells. [7]

What the cell experiments contribute

Culture studies are most useful here for explaining an observed animal effect or identifying a testable vulnerability. They carry less weight than disease control in vivo, and an altered signalling protein should not automatically be called a direct molecular target.

AML: oxidative stress and NF-κB

The 2010 work linked niclosamide to reactive oxygen species and suppression of NF-κB signalling. Across 81 primary leukemia samples—68 AML, 10 ALL and 3 CML—the median 72-hour IC₅₀ was 0.129 µM, with a wide range. These were cells from patients, not patients receiving treatment. [2]

CML: reducing BCR-ABL expression

In the T315I study, niclosamide reduced Sp1-dependent BCR-ABL transcription. Seventy-two-hour IC₅₀ values were approximately 0.58–0.65 µM in KBM5 models and 2.31 µM in K562 cells. This proposed mechanism differs from directly occupying the kinase’s drug-binding site. [3]

T-ALL: metabolic disruption

The 2024 study linked 1–4 µM niclosamide exposure to lower transketolase activity, ATP and measures of respiration and glycolysis. This supports metabolic disruption, but does not by itself prove direct binding to transketolase. [4]

B-ALL: ROS and apoptotic signalling

The 2024 B-ALL work implicated oxidative stress and the TP53–PUMA/NOXA response. Some mechanistic experiments used 10 µM niclosamide. Those experiments help explain cellular responses, but need exposure justification before being treated as clinically actionable. [6]

These findings describe several context-dependent responses, rather than a universally demonstrated set of targets in every leukemia subtype. Activity in one cell line or molecular background cannot establish equal sensitivity across AML, CML, B-ALL and T-ALL.

Combination activity depends on context and timing

Chemotherapy: the sequence can reverse the result

In the 2018 AML study, simultaneous niclosamide plus cytarabine or daunorubicin was antagonistic in HL-60 cultures (combination index > 2). Niclosamide pretreatment for three days followed by chemotherapy instead produced synergy; chemotherapy-first exposure reduced niclosamide’s effect. These are laboratory scheduling results, not a validated clinical sequence. [5]

Earlier AML experiments reported synergy with chemotherapy under their tested conditions. The difference reinforces why a combination should be judged by its actual concentrations, schedule and model, rather than by putting two plausible mechanisms beside each other. [2]

Azacitidine in TP53-mutated disease

A 2024 study tested niclosamide with azacitidine in TP53-mutated MDS/AML. In a mouse model mixing wild-type and R273H-mutant MOLM-13 cells, the combination reduced leukemia burden and countered enrichment of the mutant population seen with azacitidine. Niclosamide was given at 100 mg/kg orally. In the separate survival experiment, niclosamide was administered daily for 14 days alongside a seven-day course of azacitidine at 2.5 mg/kg/day IP. The survival result was a trend, not a demonstrated statistically significant benefit. [8]

This supports further investigation of a specific resistant-clone problem. It does not establish that the combination improves survival in TP53-mutated leukemia generally, or that its effects extend to every TP53 variant.

Disulfiram/copper in KMT2A-rearranged leukemia

A 2024 study tested niclosamide with disulfiram plus copper in KMT2A/MLL-rearranged AML and ALL cells. The combination enhanced depletion of leukemia-driving fusion proteins and suppression of their downstream transcriptional programmes. Niclosamide inhibited protein translation through eIF2α phosphorylation; disulfiram disrupted fusion-protein DNA binding. [11]

Sixteen-hour protein-depletion experiments used niclosamide 5 µM in SHI-1 or 2.5 µM in SEMK2 cells, with disulfiram 0.15 µM and copper 1 µM. Separate 72-hour viability experiments tested concentration combinations with copper maintained at 1 µM. These are culture exposures, not human doses. [11, Figures 1–2]

The authors described the loss of cell viability as additive. Enhanced fusion-protein depletion should therefore not be presented as proven synergistic killing. The study was entirely in vitro: it provides no combination tumour-volume or survival data. Normal cord-blood CD34-positive colony formation was not significantly affected under the tested conditions, which does not establish clinical safety. [11]

Dose is not the same as exposure

Three distinct quantities run through these papers: the concentration surrounding cells in culture, the amount administered per kilogram to a mouse, and the concentration reaching blood or marrow over time. None can substitute for the others without pharmacokinetic measurements.

A 2025 healthy-volunteer study compared an oral solution with marketed 2,000 mg chewing tablets and found substantial variability in niclosamide exposure, a food effect and nonlinear absorption of the solution. This makes a single universal “human maximum concentration” misleading. It also means that increasing an administered dose does not necessarily increase exposure proportionally. [10]

What an exposure comparison needs

A brief total-plasma peak cannot be assumed to reproduce continuous culture exposure. The relevant comparison needs the concentration available to cells, duration above an active level, distribution into marrow and tolerability during repeated treatment. An IP mouse dose of a soluble derivative cannot be converted into an effective oral human regimen from body weight alone.

Comparisons should therefore prioritise experiments matching the proposed compound, route and disease stage, rather than selecting the largest effect regardless of how it was obtained.

A related compound shows why formulation and chemistry matter

MB1-47, a niclosamide-related mitochondrial uncoupler, reduced leukemia burden and prolonged survival in mouse T-ALL and human T-ALL xenografts. In a mouse survival protocol it was delivered in feed at an estimated 100 mg/kg/day. The work connected mitochondrial energy and metabolite depletion to impaired nucleotide synthesis and AMPK–mTOR signalling. However, single-agent treatment did not produce complete remissions, and treated leukemias eventually relapsed. [9]

This makes mitochondrial uncoupling a credible research direction. Because MB1-47 is a distinct molecule with different exposure properties, its results cannot be added to the efficacy record of ordinary niclosamide as though the agents were interchangeable.

What this evidence supports

Niclosamide and selected derivatives have a substantive preclinical leukemia signal. The evidence includes measured tumour-growth inhibition, activity in disseminated disease and functional transplantation results—not merely pathway predictions. Yet the experiments also identify the boundaries: early treatment can outperform treatment of established disease, injected derivatives dominate several positive results, combinations can be antagonistic, and delayed progression does not necessarily become durable remission.

The next decisive evidence would connect repeated drug exposure in marrow to target engagement, disease control and tolerability in established-disease models, followed by appropriately designed human trials. The animal results justify that investigation; they do not establish niclosamide as an effective leukemia treatment in people.

Sources and evidence notes

A focused review of primary studies, not a systematic review or meta-analysis. Animal findings are prioritised; culture findings are labelled separately. Percentages in the volume table are calculations from published group means, not author-reported response rates. No percentages were estimated from graph images.

  1. Huang et al. Niclosamide in T-ALL: apoptosis, autophagy and xenograft growth. Oncology Reports, 2022. Figure 5. Timing follows methods; the caption describes duration inconsistently.
  2. Jin et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells. Cancer Research, 2010. NF-κB/ROS, primary-cell assays and p-niclosamide HL-60 xenografts.
  3. Jin et al. Niclosamide suppresses BCR-ABL transcription via Sp1 and induces apoptosis in imatinib-resistant CML cells harbouring T315I. Cell Death & Disease, 2018. Subcutaneous and disseminated models are distinct experiments.
  4. Huang et al. Regulating TKT activity inhibits proliferation of human acute lymphoblastic leukemia cells. American Journal of Cancer Research, 2024. Metabolic assays and CCRF-CEM xenografts.
  5. Chae et al. Niclosamide, CREB signalling and AML. Oncotarget, 2018.
  6. Antitumor activity of niclosamide-mediated oxidative stress against acute lymphoblastic leukemia. Carcinogenesis, 2024. B-ALL culture mechanisms and injected p-niclosamide in systemic NALM-6-Luc disease.
  7. Jin et al. Niclosamide disrupts the interplay of p65 and FOXM1/β-catenin in CML leukemia stem cells. Clinical Cancer Research, 2017. Self-renewal and secondary-transplantation assays.
  8. Niclosamide combined to azacitidine to target TP53-mutated MDS/AML cells. Leukemia, 2024. Primary-cell and mixed-clone mouse experiments; dosing details also in the supplement.
  9. A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia. Blood, 2021. MB1-47 is a separate niclosamide-related molecule.
  10. Walther et al. Clinical safety and pharmacokinetics of an oral niclosamide formulation compared with marketed chewing tablets in healthy volunteers. PLOS ONE, 2025. Human pharmacokinetics, not leukemia efficacy.
  11. Che et al. Enhanced depletion of MLL-fusion proteins in acute leukemia: potential for improved therapeutic outcomes. Experimental Hematology & Oncology, 2024.

No comments:

Post a Comment